Scientific Articles COVID-19 articles

terapia antitrombótica triple

Are Antithrombotics Necessary in Outpatients after COVID-19?

Are Antithrombotics Necessary in Outpatients after COVID-19?

According to this recent study (soon to be published in JAMA), antithrombotic therapy has no clinical benefits for outpatients with stable symptoms of COVID-19.  Both aspirin and apixaban in therapeutic or prophylactic doses did not reduce major cardiovascular events compared against placebo, though these events are rare, which makes it difficult to show any benefit. 

Recomendaciones de la ACC con el nuevo coronavirus

Reasons Behind Increased COVID-19 Infections in a Highly Vaccinated Population

In December 2020, the healthcare workforce at San Diego University saw an unexpected increase in COVID-19 infections. Concurrently, this same month, one of the most ambitious vaccination campaigns ever was taking off, one which managed to inoculate 76% of the population by March 2021 and 87% by June same year.  Infections saw a significant reduction

Síntomas persistentes post COVID-19: mucho más frecuentes de lo que creíamos

New Evidence in Israel in Favor of Applying a Third Dose against COVID-19

According to this study carried out in Israel, patients over 60 who had received two doses against COVID-19 at least 5 months ago will benefit from an additional dose in terms of a significant reduction of severe disease. In addition, patients who unfortunately got severely ill despite receiving a third shot, were more easily managed. 

SOLACI-CACI 2021 Virtual

SOLACI-CACI 2021 | Cardiovascular Disease Management and Cath Lab During the COVID-19 Pandemic

✔️ Watch again the session on Cardiovascular Disease Management and Cath Lab During the COVID-19 Pandemic in the SOLACI-CACI 2021 Congress. 👨‍🏫 Program: 04:55 – Thromboembolic Complications in COVID – José Ceresetto 27:59 – Global Registry of Acute Myocardial Infarction of Primary PCI in COVID Era – Giuseppe De Luca 53:36 – Infectious Disease Care in

ESC 2021 | Injuria aguda y crónica por COVID-19 y su impacto en la mortalidad

ESC 2021 | Acute and Chronic Myocardial Injury in COVID-19 Patients and Impact in Mortality

In patients hospitalized for COVID-19, both acute and chronic myocardial injury impact survival at 6 months. In addition, the risk does not disappear after the acute phase of the disease, instead it persists in the following months among those who survive.  This study was presented at the scientific sessions of ESC 2021 and was simultaneously

Historia natural de la infección asintomática por COVID-19

Vaccine Efficacy against the Delta COVID-19 Variant

COVID-19 B.1.617.2 (delta) Variant, first detected in India, has contributed to a significant increase in the number of COVID cases and has inexorably spread all across the world.  The relative efficacy of BNT162b2 (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (AstraZeneca) vaccines against this new variant was unclear Vaccine efficacy against the delta symptomatic infection vs. the predominant

Síntomas persistentes post COVID-19: mucho más frecuentes de lo que creíamos

Heparin Anticoagulation in Critically Ill COVID-19 Patients: Results that Differ from the Rest

In critically ill COVID-19 patients, an initial strategy of anticoagulation with heparin did not result in any benefit compared with standard prophylactic treatment. Thrombosis and inflammation are the main issues when discussing COVID-19 related morbidity. This led to testing whether an anticoagulation scheme could improve prognosis in critically ill COVID-19 patients. Given the dynamics of

Síntomas persistentes post COVID-19: mucho más frecuentes de lo que creíamos

Surviving Covid-19 with Good Old Heparin?

Patients hospitalized for COVID-19 are at high risk for thrombosis, particularly venous thromboembolism. This information is not new: in a meta-analysis of 66 studies, the overall prevalence of venous thromboembolism among patients with COVID-19 admitted to intensive care units was between 14.1% and 22.7%. Hypercoagulability is an early-described feature of this new virus, and so is

Recomendaciones de la ACC con el nuevo coronavirus

Anticoagulation with Heparin in Non-Critical COVID-19

In non-severe COVID-19 patients, an initial therapeutic strategy with heparin increases the chance of survival after discharge and reduces the need for respiratory and cardiovascular support compared against usual thromboprophylaxis doses.  These data have been welcomed by a medical community eager to receive good news in terms of effective strategies to combat an already existing

Recomendaciones de la ACC con el nuevo coronavirus

Anosmia 1 Year After a COVID-19 Diagnosis

The number of people with post-COVID-19 syndrome seems to be growing exponentially, so we need long-term data to help physicians advise patients correctly. Among the many persistent symptoms, post-COVID-19 anosmia has good prognosis and almost full recovery at 1 year. In April, 2020, these same authors published a cohort of almost 100 COVID-19 positive patients (positive

indicación de tratamiento con estatinas

Could Statins Do More than Lower Cholesterol in COVID-19 Patients?

A history of acute myocardial Infarction, cardiac failure or hyperlipidemia has been associated with increased mortality of COVID-19. Observational studies have suggested statins might reduce death risk from COVID-19, in addition to lowering cholesterol.  Statins have anti-inflammatory and antithrombotic effects that could play a role in the course of the infection.  Other studies have arrived